Search Results for “vaccine” – Page 38 – media

Chilean President Gavriel Borich Meets with Yin Weidong, Chairman, President and CEO of SINOVAC

On December 12, 2023, local time, Chilean President Gavriel Borich met with Yin Weidong, Chairman, President and CEO of SINOVAC, and his delegation at the Presidential Palace. The two sides reached an agreement on the localization of vaccine production and cooperation in the research and development of health products, and the Chilean government will strongly support SINOVAC’s project promotion in the region. President Borich began by recalling his successful visit to China not long ago, emphasizing that when he met with President Xi Jinping, they jointly identified the need to further deepen cooperation in the health sector among the many bilateral cooperation between China and Chile. He also indicated that the Chilean government has set the strategic goal of developing vaccine R&D and industrialization in Chile. Chairman Yin Weidong responded, “His Excellency the President’s visit to China was indeed a great success, and the charisma you displayed attracted many Chinese ...
- Source: drugdu
- 98
- December 20, 2023
GLP-1 agonists can blunt obesity-associated health problems

Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year’s discovery that these drugs can blunt obesity-associated health problems as its 2023 Breakthrough of The Year. Although obesity’s causes span genetic, physiological, environmental, and social factors, as a medical problem, obesity’s risks can be life-threatening – including heart disease, diabetes, arthritis, liver disease, and certain cancers. Drug treatments for obesity have had “a sorry past, one often intertwined with social pressure to lose weight and the widespread belief that excess weight reflects weak willpower,” writes Jennifer Couzin-Frankel in the Breakthrough news feature. However, a new class of drug therapies for weight loss has emerged and is showing promising results. Originally developed to treat diabetes nearly 20 years ago, the excitement surrounding GLP-1 drugs to treat obesity has recently exploded. And this year, two landmark clinical trials that showed in large numbers that GLP-1 agonists produced meaningful ...
- Source: drugdu
- 123
- December 18, 2023
MHRA supports launch of Innovate UK’s first-of-its-kind initiative to fund new Regulatory Science and Innovation Networks

Launched yesterday (Wednesday 13 December) by Innovate UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has joined partners across government including the Office for Life Sciences to provide support and invite academic institutions in the UK to apply to become a member of an RSIN. In a drive to proactively deliver agile and robust regulatory pathways and guidance to support the innovators of today and tomorrow, the MHRA has helped shape the design of this programme with partners across government, which will enable research informing the future of UK regulatory practice. Applications can be made through UKRI’s Innovation Funding Service. Dr June Raine, MHRA Chief Executive, said: As a forward-thinking, agile, and enabling regulator in today’s fast-paced environment, we must get ready for the innovations of tomorrow. This initiative, the first-of-its-kind, is a fantastic opportunity for academic institutions in the UK to be at the cutting edge of life ...
- Source: drugdu
- 101
- December 16, 2023
Mayor of Bogota, Colombia, Claudia Lopez and Ambassador of Colombia, Sergio Cabrera and his entourage visited SINOVAC.

On the afternoon of December 5, 2023, Claudia Lopez, Mayor of Bogota, Colombia, and Sergio Cabrera, Ambassador of Colombia to China, visited SINOVAC, accompanied by Ruth Amparo Medina, Director of International Relations of Bogota City, Oscar Felipe Rueda, Commercial Counselor of the Embassy of Colombia in China, and Daniel Mesa, First Secretary of the Embassy. Accompanied by Yin Weidong, Chairman, President and CEO of the company, Yang Guang, Chief Commercial Officer, and Gao Qiang, Chief Operating Officer. Previously, SINOVAC successfully won the bidding for the Bogotá Vaccine Plant Project (“Bogotá Project”) and entered into a strategic cooperation with the Bogotá Municipal Government, in which the two parties set up a joint venture company, BogotáBio, to promote the localized production of a variety of vaccines and new vaccines in Colombia. The joint venture, BogotáBio, will promote the local production of various vaccines in Colombia as well as the research and development ...
- Source: drugdu
- 97
- December 15, 2023
Gates Foundation Delegation Visits Zhifei Biological Products Co., Ltd.

On December 1, a delegation of global health experts from the Bill & Melinda Gates Foundation (Gates Foundation) visited Beijing Zhifei Biological Products Co., Ltd., a wholly-owned subsidiary of Zhifei Biologicals, and visited the production workshop and related laboratories, and had an in-depth exchange of views on innovative topics, such as key conjugate vaccine projects. Mr. Du Lin, Executive Director of Beijing Zhifei Biological Products Co., Ltd., and others warmly received the delegation and attended the seminar. The visiting Gates Foundation delegation included clinical experts, vaccinologists and immunologists, and senior strategists. During the meeting, the Zhifei Biologicals team explained the clinical trials of key conjugate vaccine products, domestic and overseas sites and vaccine marketization, etc. The delegation introduced the incidence of relevant diseases and flow-regulation data, and made suggestions on planned clinical studies, etc. The Gates Foundation delegation fully recognized Beijing Zhifei Biological Products Co., Ltd.’s R&D strength and industrialization ...
- Source: drugdu
- 93
- December 12, 2023
Vaccinations still vital to curb illness spread

Known pathogens behind current spate of respiratory infections in parts of nation The recent surge of respiratory illnesses in China is fueled by known pathogens, and vaccination efforts are still vital to stem the spread, medical experts said on Saturday. Mi Feng, National Health Commission spokesman, said the clusters were all caused by recognized pathogens, and medical workers are dealing with them by using mature treatment plans. “Diseases induced by unknown viruses and bacteria have not been detected yet,” he told a news conference in Beijing. Mi said vaccinations must be stepped up for vulnerable groups such as older adults and children to lower the risk of infection. He said their work priorities would be to increase the supply of hospital beds, streamline the outpatient reception process and bolster the supply of online medical services to avoid large gatherings in hospitals. The spokesman urged the public to take personal precautions ...
- Source: drugdu
- 99
- December 12, 2023
Pepper wins $6.5m to develop ‘transomic’ drug discovery platform

Boston-based start-up Pepper Bio has raised $6.5m in oversubscribed seed funding to develop its Compass drug discovery platform. The financiers included venture capital companies such as NFX, Silverton Partners, Mana Ventures and others. Pepper’s CEO Jon Hu told Pharmaceutical Technology that the Compass platform provides biological maps for insight into different “-omics”- genomics, transcriptomics, proteomics and phosphoproteomics. The success rate of drug development from pre-clinical studies to regulatory approval is 3%-10%, says Hu. If one can improve this success rate, it can bring down the cost of drug approval, he adds. According to Hu, the high cost of development is driven by the cost of failed iterations of the therapy. Pepper sources its database consists of publicly and commercially available data in addition to its proprietary data, which was either generated in-house or acquired through partnerships. Hu added that public and commercial data undergoes a series of transformations including an ...
- Source: drugdu
- 96
- December 2, 2023
Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

Boehringer Ingelheim has said it will be acquiring bacterial cancer therapy specialist T3 Pharmaceuticals in a deal worth over $500m, marking a significant boost to its immuno-oncology portfolio. Boehringer said it is seeking to “significantly increase” the current 15 to 20% remission rate in cancer patients by utilising complementary immuno-oncology platforms such as T-cell engagers, oncolytic viruses and cancer vaccines. T3, founded in 2015 as a spinout from the University of Basel in Switzerland, has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins directly to cancer cells and tumour micro-environments while sparing healthy tissues. The bacteria can be loaded with multiple immune-modulatory proteins of choice, allowing the design of immuno-oncology combination therapies in one single agent. Michel Pairet, member of the board of managing directors at Boehringer with responsibility for the Innovation Unit, said: “The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline ...
- Source: drugdu
- 106
- November 25, 2023
European Patent Office Declares One of Moderna’s mRNA Patents Invalid

By Tristan Manalac The European Patent Office has decided that a hotly contested mRNA patent held by Moderna pertaining to its COVID-19 vaccine is invalid, Reuters reported on Tuesday. The patent in question covers betacoronavirus vaccines that use at least one RNA polynucleotide with an open reading frame that encodes at least one betacoronavirus antigenic peptide, according to its claims document listed in the European Patent Register. While the patent battle is over the use of this technology to produce COVID-19 vaccines, the claims document also seeks to protect its use for other viral respiratory infections, including MERS and SARS. Several biopharma companies have lodged their opposition to these claims, including BioNTech and Pfizer—Moderna’s chief competitors in the coronavirus vaccine market—as well as Sanofi, according to the patent’s listing on the register. A BioNTech spokesperson in a statement to Fierce Pharma said that the company “welcomes” the European Patent Office’s ...
- Source: drugdu
- 109
- November 24, 2023
Novartis drops subpoena request in trade-secret spat with Takeda

Novartis has withdrawn its request to access Takeda’s documents as part of an investigation over potential trade secrets theft. Novartis originally filed the complaint in Massachusetts Superior Court in October. The Swiss pharma wanted to find out whether a former employee in Egypt took sensitive documents to his new job with Takeda. After being “stonewalled” by Takeda, Novartis resorted to legal action, attempting to subpoena the Japanese pharma’s business records and depose an employee. Takeda, on Nov. 10, filed a motion to dismiss the complaint for recovery. According to Novartis, a former employee named Khaled Shams Eldin transferred some 10,000 files to his personal email before departing the company in May. After leaving his post as operations lead for cell and gene therapy at Novartis’ Egyptian unit, Eldin joined Takeda in July in a similar position, the company said. Earlier this week, Novartis dropped the case, according to a court ...
- Source: drugdu
- 114
- November 24, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.